Demand for Preimplantation Genetic Diagnosis Market is Escalating Due to Promising Fertility Rate

 

Preiplantation Genetic Diagnosis is offering to help those who aren't sure if they can have children of their own or if they'll have problems with certain medical issues in the future. Pregnancy and Fertility are two other reasoned explanations why this test could be offered. The task is performed when the couple is preparing for conception by checking for just about any irregularities on an ultrasound. The genetic information from the unaffected parents and the affected eggs are compared to find out if your genetic problem exists with the egg of one of the partners.

The growing amount of fertility clinics around the planet in conjunction with the advancement in the field of genetic analysis is driving the marketplace growth of Preimplantation Genetic Diagnosis Market. The increasing dependence on early detection of chromosomal abnormalities in the fetus is another major factor fueling the marketplace growth of preimplantation genetic testing. The advent of next-generation sequencing (NGS) can be adding to the marketplace growth. Furthermore, the growing prevalence of gene-related disorders is further anticipated to augment the marketplace growth of preimplantation genetic testing. Additionally, growing awareness regarding genetic testing of a particular gene mutation among healthcare workers is again anticipated to foster market growth. Also, increasing maternal age and growing incidence of aneuploidy is anticipated to uplift the marketplace growth in the near future.

From the geographical perspective, North America is expected to gain significant growth within the forecast period and this really is attributed to the high incidence of the gene-related disorder in the region. Based on the U.S. Department of Health and Human Services, about 1 in 200,000 people in the United States are born with syndrome A each year. Around 1 in 100,000 people in the United States have syndrome A at the present time.

Key Developments:

In October 2019, PerkinElmer, Inc., a worldwide provider of innovating for a healthy world, introduced it's PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Diagnosis Market for Aneuploidy (PGT-A) kit. This solution tests spent embryo culture media for chromosomal abnormalities during in vitro fertilization (IVF) treatment.

In October 2018, Vitrolife AB (publ) has entered in to a License and Commercialisation Agreement with Illumina, Inc., which provides Vitrolife with exclusive distribution, development, and commercialization rights to Illumina's preimplantation genetic testing business for IVF in EMEA and Americas.

In July 2020, Chromosome Medicina Genômica, powered by GeneOne, enter in to a partnership with Genomic Prediction and Diagnostics da America (DASA), to introduce LifeView™ PGT-P to Brazil.